Dysregulation of Glucose Metabolism by Oncogenes and Tumor Suppressors in Cancer Cells
Open accessThe DOI matches its OpenAlex record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Cancers are complex diseases having several unique features, commonly described as ‘hallmarks of cancer’. Among them, altered signaling pathways are the common characteristic features that drive cancer progression; this is achieved due to mutations that lead to the activation of growth promoting(s) oncogenes and inactivation of tumor suppressors. As a result of which, cancer cells increase their glycolytic rate by consuming a large amount of glucose, and convert a majority of glucose to lactate even in the presence of oxygen known as the “Warburg effect”. Tumor cells like other cells are strictly dependent on energy for growth and survival; therefore, understanding energy metabolism will give us an idea to develop new effective anti-cancer therapies that target cancer energy production pathways. This review summarizes the roles of tumor suppressors and oncogenes and their products that provide metabolic advantages to cancer cells which in turn leads to the establishment of the “Warburg effect” and ultimately leads to cancer progression. Understanding cancer cell’s vulnerability will provide potential targets for its control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Mitochondrial Autophagy Is an HIF-1-dependent Adaptive Metabolic Response to Hypoxia
Zhang, H., Bosch-Marce, M., Shimoda, L. A., Tan, Y. S., Baek, J. H., Wesley, J. B., Gonzalez, F. J., & Semenza, G. L. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800102200 · Cited by 1,601 · cited 1×
“Furthermore, HIF-1 activates PKM2 gene transcription (Zhang et al., 2008).”
RetractedThe Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088 · cited 6×
“Therefore, in p53- deficient cell or cell harboring mutp53, HIF and cMyc promotes the expression of several glycolytic enzymes (HK-II, PFK1, PGM) (Dang et al., 1997; Dang, 2007; DeBerardinis et al., 2008a; DeBerardinis et al., 2008b; Denko, 2008; Vander and Cantley, 2009) HK-II increases the production G-6P in the cyt…”
BackgroundInfluentialKim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905
Otto Warburg's contributions to current concepts of cancer metabolism
Koppenol, W. H., Bounds, P. L., & Dang, C. V. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3038 · Cited by 3,427 · cited 8×
“Mutated K-ras upregulate glucose transporter protein 1 (GLUT1) expression leading to an increase in aerobic glycolysis by cancer cells (Figure 2) (Annibaldi and Widmann, 2011).”
BackgroundInfluentialRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“Furthermore, an E3 ubiquitin ligase MDM2 protein cannot target mutp53 for degradation leading to its stabilization (Kubbutat et al., 1997) and can exert additional promoting functions (Muller et al., 2013).”
BackgroundMetabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233 · cited 2×
“Therefore, a control system is required to prevent unwanted uptake of glucose because cells do not take glucose from the surrounding environment based on needs but based on instructions from growth factors through receptor tyrosine kinases (RTKs) (Ward and Thompson, 2012).”
BackgroundDeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., & Thompson, C. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709747104 · Cited by 2,622
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption
Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.012 · Cited by 2,267
Gao, P., Tchernyshyov, I., Chang, T.-C., Lee, Y.-S., Kita, K., Ochi, T., Zeller, K. I., De Marzo, A. M., Van Eyk, J. E., Mendell, J. T., et al. (2009) · Nature · doi:10.1038/nature07823 · Cited by 2,124
Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis
Chipuk, J. E., Kuwana, T., Bouchier-Hayes, L., Droin, N. M., Newmeyer, D. D., Schuler, M., & Green, D. R. (2004) · Science · doi:10.1126/science.1092734 · Cited by 2,108 · cited 1×
“If the damage is unrepairable, p53 induced cell death through the expression of apoptotic proteins such as PUMA, NOXA or BAX (Villunger et al., 2003; Chipuk et al., 2004), thus preventing cellular transformation and tumor development.”
BackgroundTIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019 · cited 9×
“In response to DNA damage, p53 indirectly reduced the level of fructose 2,6-bisphosphate by increasing the expression of TP53-induced glycolysis and apoptosis regulator (TIGAR), which exhibits sequence similarity to the bisphosphatase2 domain of PFK2/FBPase and is able to reduce the glycolytic flux (Bensaad et al., 20…”
BackgroundInfluentialWise, D. R., DeBerardinis, R. J., Mancuso, A., Sayed, N., Zhang, X.-Y., Pfeiffer, H. K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S. B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810199105 · Cited by 2,001
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression
Shackelford, D. B., & Shaw, R. J. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2676 · Cited by 1,943 · cited 6×
“Consequently, AMPK suppress anabolic processes by blocking protein translation and fatty acid (FA) synthesis (Jones et al., 2005; Kuhajda, 2008; Shackelford and Shaw, 2009) and is responsible for shifting cell to an oxidative phosphorylation (Shaw et al.”
BackgroundInfluentialThe functions and regulation of the PTEN tumour suppressor
Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926
HIF-1α pathway: role, regulation and intervention for cancer therapy
Masoud, G. N., & Li, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.05.007 · Cited by 1,871 · cited 3×
“Similarly, wild type p53 also repressed the expression of hexokinase 2 (HK-II) by interacting with the promoter genes coding for HK-II, which control the production of glucose-6phosphate (G6P) (Mathupala et al., 1997).”
BackgroundShaw, R. J., Kosmatka, M., Bardeesy, N., Hurley, R. L., Witters, L. A., DePinho, R. A., & Cantley, L. C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308061100 · Cited by 1,797
Hypoxia, HIF1 and glucose metabolism in the solid tumour
Denko, N. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2468 · Cited by 1,707
LKB1 is the upstream kinase in the AMP-activated protein kinase cascade
Woods, A., Johnstone, S. R., Dickerson, K., Leiper, F. C., Fryer, L. G. D., Neumann, D., Schlattner, U., Wallimann, T., Carlson, M., & Carling, D. (2003) · Current Biology · doi:10.1016/j.cub.2003.10.031 · Cited by 1,650
p53 Regulates Mitochondrial Respiration
Matoba, S., Kang, J.-G., Patino, W. D., Wragg, A., Boehm, M., Gavrilova, O., Hurley, P. J., Bunz, F., & Hwang, P. M. (2006) · Science · doi:10.1126/science.1126863 · Cited by 1,650 · cited 3×
“Besides its involvement in the cytosol, p53 also plays a major role in the mitochondria by increasing the synthesis of cytochrome c oxidase 2 genes, which is required for the assembly of the cytochrome oxidase complex (COX) of the electron transport chain, thereby enhanced oxidative phosphorylation (Matoba et al., 200…”
BackgroundInfluentialAMP-activated protein kinase induces a p53-dependent metabolic checkpoint
Jones, R. G., Plas, D. R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M. J., & Thompson, C. B. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.027 · Cited by 1,619
Kruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610
Hawley, S. A., Pan, D. A., Mustard, K. J., Ross, L., Bain, J., Edelman, A. M., Frenguelli, B. G., & Hardie, D. G. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.009 · Cited by 1,589
Regulation of translation initiation by FRAP/mTOR
Gingras, A.-C., Raught, B., & Sonenberg, N. (2001) · Genes & Development · doi:10.1101/gad.887201 · Cited by 1,545 · cited 1×
“Specifically, PTEN dephosphorylates PIP3, preventing Akt1 activation, thereby directly antagonizing the PI3K function and blocking, therefore the activation of downstream signaling events, including PDK1, (Akt) and Akt/mammalian target of rapamycin (mTOR) (Gingras et al., 2001).”
BackgroundHypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514
Akt Stimulates Aerobic Glycolysis in Cancer Cells
Elstrom, R. L., Bauer, D. E., Buzzai, M., Karnauskas, R., Harris, M. H., Plas, D. R., Zhuang, H., Cinalli, R. M., Alavi, A., Rudin, C. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2904 · Cited by 1,454
p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa
Villunger, A., Michalak, E. M., Coultas, L., Müllauer, F., Böck, G., Ausserlechner, M. J., Adams, J. M., & Strasser, A. (2003) · Science · doi:10.1126/science.1090072 · Cited by 1,327
The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes
Levine, A. J., & Puzio-Kuter, A. M. (2010) · Science · doi:10.1126/science.1193494 · Cited by 1,243 · cited 1×
“Aberrant activation of this pathway drives tumor progression independence on extrinsic growth factor stimulation (the hallmark of cancer) (Li et al., 2015).”
BackgroundHnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer
David, C. J., Chen, M., Assanah, M., Canoll, P., & Manley, J. L. (2010) · Nature · doi:10.1038/nature08697 · Cited by 1,179
Oncogenic alterations of metabolism
Dang, C. V., & Semenza, G. L. (1999) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(98)01344-9 · Cited by 1,106
Links between metabolism and cancer
Dang, C. V. (2012) · Genes & Development · doi:10.1101/gad.189365.112 · Cited by 1,100
c-Myc transactivation of LDH-A : Implications for tumor metabolism and growth
Shim, H., Dolde, C., Lewis, B. C., Wu, C.-S., Dang, G., Jungmann, R. A., Dalla-Favera, R., & Dang, C. V. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6658 · Cited by 1,092 · cited 2×
“Like HIF, c-Myc also has huge influences on glucose metabolism by up-regulating gene expression of many glycolytic enzymes from glucose transporters through pyruvate kinase as well as lactate dehydrogenase A, thereby allowing efflux of glucose-derived carbon as lactate (Shim et al., 1997; Osthus et al., 2000).”
BackgroundRestoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · cited 1×
“Another strategy is to restore the structural integrity of mutant p53 by a compound that acts as a chaperone (Bykov et al., 2002).”
BackgroundLKB1 modulates lung cancer differentiation and metastasis
Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., et al. (2007) · Nature · doi:10.1038/nature06030 · Cited by 1,064
Brick by brick: metabolism and tumor cell growth
DeBerardinis, R. J., Sayed, N., Ditsworth, D., & Thompson, C. B. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.02.003 · Cited by 1,018
Ema, M., Taya, S., Yokotani, N., Sogawa, K., Matsuda, Y., & Fujii-Kuriyama, Y. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4273 · Cited by 1,016 · cited 2×
“HIF-1α is ubiquitously expressed in the body, which is primarily involved in transcriptional activation of many glycolytic genes (Masoud and Lin, 2015) whereas HIF-2α expression is stricter to specific tissues such as endothelial, lung, renal, and hepatic cells and does not involve in glucose metabolism directly, but…”
BackgroundGottlob, K., Majewski, N., Kennedy, S., Kandel, E., Robey, R. B., & Hay, N. (2001) · Genes & Development · doi:10.1101/gad.889901 · Cited by 961 · cited 1×
“Recent discovery show that both HIF-1α and HIF-2α are directly interact with the mitochondrial pore to prevent the release of apoptotic proteins (Gottlob et al., 2001; Pastorino et al., 2002; Miyamoto et al., 2008).”
BackgroundVousden, K. H., & Ryan, K. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2715 · Cited by 959 · cited 4×
“Besides its involvement in DNA damage, repairs and apoptosis, p53 also play major roles in metabolism by decreasing the glycolytic rate (Vousden and Ryan, 2009).”
BackgroundInfluentialHIF-1 and human disease: one highly involved factor
Semenza, G. L. (2000) · Genes & Development · doi:10.1101/gad.14.16.1983 · Cited by 909 · cited 3×
“Subsequently, the HIF-1 dimer (i.e. the active complex of HIF-1α and HIF-1β) binds to the hypoxia response element of target genes (Semenza, 2000b; Maxwell and Pugh, 2001; Gordan et al., 2007; Semenza, 2012) resulting in their transcriptional activation.”
BackgroundGlutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function
Hu, W., Zhang, C., Wu, R., Sun, Y., Levine, A., & Feng, Z. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001006107 · Cited by 862
Signal transduction to hypoxia-inducible factor 1
Semenza, G. L. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01168-1 · Cited by 860 · cited 1×
“Asian Pacific Journal of Cancer Prevention, Vol 19 2381 DOI:10.22034/APJCP.2018.19.9.2377 Dysregulation of Glucose Metabolism the HIF-1α protein translation (Conrad et al., 1999; Jiang et al., 2001; Semenza, 2002).”
BackgroundInfluentialCharacterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor
Hirsilä, M., Koivunen, P., Günzler, V., Kivirikko, K. I., & Myllyharju, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304982200 · Cited by 794
HIF-2α Promotes Hypoxic Cell Proliferation by Enhancing c-Myc Transcriptional Activity
Gordan, J. D., Bertout, J. A., Hu, C.-J., Diehl, J. A., & Simon, M. C. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.006 · Cited by 781
Suzuki, S., Tanaka, T., Poyurovsky, M. V., Nagano, H., Mayama, T., Ohkubo, S., Lokshin, M., Hosokawa, H., Nakayama, T., Suzuki, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002459107 · Cited by 705
Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells
Yuneva, M., Zamboni, N., Oefner, P., Sachidanandam, R., & Lazebnik, Y. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200703099 · Cited by 690
Serine is a natural ligand and allosteric activator of pyruvate kinase M2
Chaneton, B., Hillmann, P., Zheng, L., Martin, A. C. L., Maddocks, O. D. K., Chokkathukalam, A., Coyle, J. E., Jankevics, A., Holding, F. P., Vousden, K. H., et al. (2012) · Nature · doi:10.1038/nature11540 · Cited by 661
Glycolytic Enzymes Can Modulate Cellular Life Span
Kondoh, H., Lleonart, M. E., Gil, J., Wang, J., Degan, P., Peters, G., Martinez, D., Carnero, A., & Beach, D. (2005) · Cancer Research · doi:10.1158/0008-5472.177.65.1 · Cited by 647 · cited 8×
“Mutated K-ras upregulate glucose transporter protein 1 (GLUT1) expression leading to an increase in aerobic glycolysis by cancer cells (Figure 2) (Annibaldi and Widmann, 2011).”
BackgroundInfluentialOn respiratory impairment in cancer cells
Weinhouse, S. (1956) · Science · doi:10.1126/science.124.3215.267 · Cited by 554
Targeting the PI3K signaling pathway in cancer
Wong, K.-K., Engelman, J. A., & Cantley, L. C. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.11.002 · Cited by 543
Roles of p53, MYC and HIF-1 in regulating glycolysis–the seventh hallmark of cancer
Yeung, S. J., Pan, J., & Lee, M.-H. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8224-x · Cited by 514 · cited 4×
“…single nucleotide polymorphisms, and chromosomal translocations (Prendergast and Ziff, 1992). c-Myc expression promotes energy production and anabolic processes, which are required for rapid proliferation, independent of growth factor stimulation (Gordan et al., 2007; Yeung et al., 2008).”
BackgroundInfluentialThe p53 orchestra: Mdm2 and Mdmx set the tone
Wade, M., Wang, Y. V., & Wahl, G. M. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.01.009 · Cited by 450
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
Normanno, N., Tejpar, S., Morgillo, F., De Luca, A., Van Cutsem, E., & Ciardiello, F. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.111 · Cited by 436 · cited 1×
“Another oncogene, K-ras, has been found to be frequently mutated in some type of cancer (Normanno et al., 2009).”
BackgroundTumour-associated mutant p53 drives the Warburg effect
Zhang, C., Liu, J., Liang, Y., Wu, R., Zhao, Y., Hong, X., Lin, M., Yu, H., Liu, L., Levine, A. J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3935 · Cited by 434 · cited 6×
“The GLUT3 expression is stimulated by the IKK/nuclear factor-κB pathway, p53 inhibit this pathway and indirectly reduces GLUT3 expression (Kawauchi et al., 2008).”
BackgroundInfluentialMitochondrial complex III regulates hypoxic activation of HIF
Klimova, T., & Chandel, N. S. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402307 · Cited by 433
Guzy, R. D., Sharma, B., Bell, E., Chandel, N. S., & Schumacker, P. T. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01338-07 · Cited by 427 · cited 1×
“ROS generated from complexes II and III in the mitochondria also mediates HIF-1α stabilization (Guzy et al., 2005; Guzy et al., 2008; Klimova and Chandel, 2008).”
BackgroundHeterogeneity of tumor-induced gene expression changes in the human metabolic network
Hu, J., Locasale, J. W., Bielas, J. H., O'Sullivan, J., Sheahan, K., Cantley, L. C., Heiden, M. G. V., & Vitkup, D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2530 · Cited by 407
Rethinking the Warburg Effect with Myc Micromanaging Glutamine Metabolism
Dang, C. V. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3556 · Cited by 379 · cited 1×
“This provides anatomical information about glucose intake on PET image (Dang, 2010; Palaskas et al., 2011).”
BackgroundMAPK Signaling Up-regulates the Activity of Hypoxia-inducible Factors by Its Effects on p300
Sang, N., Stiehl, D. P., Bohensky, J., Leshchinsky, I., Srinivas, V., & Caro, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209702200 · Cited by 370 · cited 2×
“…is not only involved in regulation of HIF-1α synthesis but also phosphorylates the co-activator CBP/ p300 which further stabilized the binding of the active complex (i.e HIF-1α, HIF-1β and co-activator CBP/300) with RNA polymerase to positively modulates genes expression (Sang et al., 2003).”
BackgroundBuzzai, M., Bauer, D. E., Jones, R. G., DeBerardinis, R. J., Hatzivassiliou, G., Elstrom, R. L., & Thompson, C. B. (2005) · Oncogene · doi:10.1038/sj.onc.1208622 · Cited by 357 · cited 2×
“However, in the absence of an abundant supply of nutrients such as glucose, this pathway is ineffective and the cell must rely on other sources of ATP generation such as fatty acid oxidation (Buzzai et al., 2005).”
BackgroundKeeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4
Marine, J.-C., Francoz, S., Maetens, M., Wahl, G., Toledo, F., & Lozano, G. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401912 · Cited by 352 · cited 1×
“In an unstressed cell, wild-type p53 is associated with an E3 ubiquitin ligase enzyme MDM2 that target p53 for degradation thus maintained the basal expression of p53 (Marine et al., 2006).”
BackgroundMinchenko, O., Opentanova, I., & Caro, J. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)01179-7 · Cited by 236
Hot-spot mutants of p53 core domain evince characteristic local structural changes
Wong, K.-B., DeDecker, B. S., Freund, S. M. V., Proctor, M. R., Bycroft, M., & Fersht, A. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8438 · Cited by 221
EPAS1 trans-activation during hypoxia requires p42/p44 MAPK
Conrad, P. W., Freeman, T. L., Beitner-Johnson, D., & Millhorn, D. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.47.33709 · Cited by 178 · cited 1×
“Asian Pacific Journal of Cancer Prevention, Vol 19 2381 DOI:10.22034/APJCP.2018.19.9.2377 Dysregulation of Glucose Metabolism the HIF-1α protein translation (Conrad et al., 1999; Jiang et al., 2001; Semenza, 2002).”
BackgroundInfluentialPRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.
(2008) · PubMed Central · doi:10.3233/clo-2008-0440 · Cited by 68
Cited by
The anti-cancer effect of quercetin: molecular implications in cancer metabolism
Reyes-Farias, M., & Carrasco-Pozo, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133177 · Cited by 689
“Major oncogenes, such as c-Myc, and HIF-1α, are reported to be master inducers of cancer glycolysis through direct or indirect transactivation of cancer glycolytic genes [33].”
BackgroundGLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer
Wu, Q., ba-alawi, W., Deblois, G., Cruickshank, J., Duan, S., Lima-Fernandes, E., Haight, J., Tonekaboni, S. A. M., Fortier, A.-M., Kuasne, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18020-8 · Cited by 305
Shuvalov, O., Kirdeeva, Y., Fefilova, E., Netsvetay, S., Zorin, M., Vlasova, Y., Fedorova, O., Daks, A., Parfenyev, S., & Barlev, N. (2023) · Metabolites · doi:10.3390/metabo13050656 · Cited by 21
Daks, A., Shuvalov, O., Fedorova, O., Petukhov, A., Lezina, L., Zharova, A., Baidyuk, E., Khudiakov, A., & Barlev, N. A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.706668 · Cited by 15
Metadata
- Authors
- Marbaniang, C., & Kma, L.
- Venue
- PubMed
- Publisher
- National Institutes of Health
- Published
- 2018-09-26
- Volume
- 19
- Issue
- 9
- Pages
- 2377-2390
- OpenAlex
- W2890701679
- Cited by
- 79
- References
- 64
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.